Abnormal regulation of pyridoxal 5'-phosphate in Reye's syndrome.
Seeking to determine the effect of liver disease associated with Reye's syndrome on the regulation of plasma pyridoxal 5'-phosphate, we measured this compound in plasma from 11 patients with biopsy-proven Reye's syndrome. Its concentrations in plasma are significantly higher [37.5 (SD 6.13) micrograms/L] at the onset of the disease than after treatment [8.50 (SD 2.9) micrograms/L] or in a group of hospitalized patients with no evidence of liver disease [8.4 (SD 1.5) micrograms/L]. The concentration of pyridoxal 5'-phosphate in plasma at the time the patients entered the hospital correlated significantly with their activities of serum alanine aminotransferase.
D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007902:Length of Stay; D008107:Liver Diseases / Q000097:blood* / Q000150:complications; D008297:Male; D011732:Pyridoxal Phosphate / Q000097:blood*; D012202:Reye Syndrome / Q000097:blood* / Q000150:complications
D011732:Pyridoxal Phosphate; D000410:Alanine Transaminase